[JAK inhibitor].

Kunihiro Yamaoka, Yoshiya Tanaka

研究成果: Review article査読

抄録

Biologics targeting inflammatory cytokine has become a standardized tool for remission induction in rheumatoid arthritis (RA). However, it is handled under restricted conditions and their cost of acquisition is high. Small molecule drugs targeting Janus kinase (JAK), a molecule involved in intracellular signaling pathway has shown similar treatment effect as biologics. Moreover, inhibitory effect on bone destruction has been demonstrated and has been approved in 2012 as a new disease modifying anti-rheumatic drug in USA. However, since the inhibition of JAK results in inhibition of multiple cytokine signaling pathways, the clinical studies have also shown adverse events differing from biologics.

本文言語English
ページ(範囲)1243-1247
ページ数5
ジャーナルUnknown Journal
71
7
出版ステータスPublished - 2013 7

ASJC Scopus subject areas

  • 医学(全般)

フィンガープリント

「[JAK inhibitor].」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル